Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone levels in cochlear perilymph after intratympanic application
2017-002377-19Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triamcinolone acetonide in sensorineural hearing loss (SNHL), sponsored by Medical University of Vienna. Primary endpoint: Triamcinolone acetonide levels in cochlear perilymph, blood and cerebrospinal fluid. Started Aug 2017; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on 2017-002377-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002377-19.